The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.
A possible timing crunch threatening Mirati’s delayed Kras inhibitor might not now happen.
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.